Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RE-LY Study)

Next Previous
X
Search
Trial Profile

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RE-LY Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Embolism; Stroke; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms RE-LY
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 04 Apr 2022 Results of a pooled analysis ((RE-LY and ARISTOTLE) analysis assessed the usefulness of biomarker-based ABC-AF scores to estimate the risks of stroke and bleeding presented at the 71st Annual Scientific Session of the American College of Cardiology
    • 05 Jan 2022 Results of meta-analysis of 4 studies (RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48) assessing the effect modification with a Cox regression model as well as across the spectrum of age as a continuous covariate, published in the Circulation.
    • 12 Nov 2020 Results of systematic review and meta-analysis of 4 studies (RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48) assessing efficacy and safety of DOAC agents compared to warfarin for patients with various levels of anticoagulation control as reflected by their time in therapeutic range (TTR), published in the American Journal of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top